Eczema (Atopic Dermatitis) Clinical Trials in Alexandria
View 59 new treatments for Eczema (Atopic Dermatitis) in Alexandria, VA. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Ruxolitinib Cream for Atopic Dermatitis/Eczema
Incyte Clinic, Burke + 1 more
This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Nemolizumab for Eczema
Galderma Clinic, Burke + 2 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Amlitelimab for Atopic Dermatitis (COAST 2)
Sanofi Clinic, Arlington + 1 more
This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Lebrikizumab for Eczema
Eli Lilly Clinic, Burke + 1 more
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Amlitelimab for Eczema
Sanofi Clinic, Arlington + 1 more
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal. Study details include: The study duration will be up to 64 weeks (for participants not entering the LTS17367 \[RIVER-AD\] study) including a 48-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 48 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 48 visit of EFC17600 (ESTUARY). The total treatment duration will be up to 48 weeks. The total number of visits will be up to 14 visits (or 13 visits for those entering LTS17367 \[RIVER-AD\] study).Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Nemolizumab for Prurigo Nodularis
Galderma Clinic, Fairfax + 1 more
This trial is testing the safety of nemolizumab, a medication for people with prurigo nodularis. Prurigo nodularis is a skin condition that causes itchy, hard lumps. Nemolizumab aims to reduce itching and swelling by blocking certain signals in the body.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
SCD-044 for Eczema
Sun Clinic, Arlington + 1 more
This trial is testing a new medication called SCD-044 to see if it can help people with moderate to severe atopic dermatitis by reducing symptoms like itching and inflammation.Show More
Waitlist
Phase 2
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Page 1 of 1
Frequently Asked Questions
Explore related conditions